Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia
Status:
NOT_YET_RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to find the best dose of zanubrutinib when used together with high-dose dexamethasone for adults who are newly diagnosed with primary immune thrombocytopenia (ITP), and to learn how safe and effective this combination treatment is.